Company / R&D per Share
FATE THERAPEUTICS INC R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.18
FY2025
5-year range
$1.00 / $3.29
FY2021-FY2025
Trend
-32.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $3.29 to $1.18 over the past 2 years.
Based on SEC 10-K filings.
1.18 in FY2025 with a 5-year CAGR of +9.9%.
Declined from $3.29 to $1.18 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -3.3%
- 5-Year CAGR
- +9.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share decreased 32.3% year-over-year.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.18 | -32.3% |
| FY2024 | $1.75 | -46.9% |
| FY2023 | $3.29 | +151.0% |
| FY2022 | $1.31 | +31.2% |
| FY2021 | $1.00 | +35.2% |
| FY2020 | $0.74 | +39.3% |
| FY2019 | $0.53 | +5.7% |
| FY2018 | $0.50 | +4.7% |
| FY2017 | $0.48 | -16.1% |
| FY2016 | $0.57 | -2.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026